Dr. Timothy O'Brien, MD

Dr. O'Brien practices at University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System.

Dr. O'Brien's NPI, 1487728937, was assigned on November 17, 2006. Dr. O'Brien graduated from University of Rochester School of Medicine and Dentistry in 1989. Dr. O'Brien holds Ohio license 35063278.

Dr. O'Brien's primary practice is University Hospitals Cleveland Medical Center, at 11100 Euclid Avenue, Cleveland, OH 44106 in Cuyahoga County. The practice phone is (216) 844-1000.

Dr. O'Brien's primary practice is University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System. Dr. O'Brien is also affiliated with MetroHealth Main Campus Medical Center. The medical group on file is University Hospitals Medical Practices. Dmand AI also links Dr. O'Brien to 4 more hospitals and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. O'Brien practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. O'Brien's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. O'Brien is licensed in Ohio.

CMS data shows 67 Medicare services from Dr. O'Brien across 2 procedure codes in 2024, all of them office visits, for 39 Medicare patients. Medicare paid $6,578 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 39 Medicare patients who saw Dr. O'Brien in 2024. The largest group is 65 to 74, with 19 patients. 69% of them have high cholesterol, and 67% have high blood pressure. Their average risk score is 2.35, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. O'Brien's median patient age at 72, with 48% women.

In 2024, Dr. O'Brien wrote 179 Medicare Part D claims for 24 patients. 87% of them were for generic drugs. CMS names the drug for 102 of them, across 6 drugs with 11 or more claims each, at $362,273 in total drug cost. In 2021, CMS named 390 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. O'Brien for performance year 2024, reported as part of a group. Dr. O'Brien accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. O'Brien as offering telehealth.

Dmand AI links 7 papers to Dr. O'Brien, published from 2019 to 2024. 2019 was the busiest year, with 2. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols and Lenalidomide. Dr. O'Brien's most frequent co-authors are Paolo F. Caimi, MD, Brenda W. Cooper, MD and Marcos Jose Garcia De Lima, MD.

Dmand AI links Dr. O'Brien to 4 clinical trials, 2 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Mantle-Cell and Multiple Myeloma. ECOG-ACRIN Cancer Research Group sponsors the most, 2.

CMS Open Payments shows 19 general payments to Dr. O'Brien from 14 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 92% of the total. Sanofi and Genzyme US Companies paid the most, $84.

Dr. O'Brien graduated from University of Rochester School of Medicine and Dentistry in 1989.